NCT06993870 Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
| NCT ID | NCT06993870 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Condition | Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-06-16 |
| Primary Completion | 2026-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-06-16 with a primary completion date of 2026-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Male or female subjects, age 18 years or older. 2. Histologically and/or cytologically documented advanced or measurable solid tumors. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Life expectancey \> = 3 months. 5. Willingness to provide written informed consent for the study. Exclusion Criteria: 1. Known uncontrolled or symptomatic central nervous system metastatic disease. 2. Subjects must have recovered (≤ Grade 1 or pretherapy baseline) from AEs due to previously administered therapies. (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0). 3. Inadequate organ or bone marrow function. 4. Pregnant or breast-feeding woman. 5. Known allergies, hypersensitivity, or intolerance to HBT-708 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Frequently Asked Questions
Who can join the NCT06993870 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06993870 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06993870 currently recruiting?
Yes, NCT06993870 is actively recruiting participants. Visit ClinicalTrials.gov or contact Shenyang Sunshine Pharmaceutical Co., LTD. to inquire about joining.
Where is the NCT06993870 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06993870 clinical trial?
NCT06993870 is sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. The trial plans to enroll 60 participants.